Competitive Advantages
Which advantages over its rivals hold up, and why are they hard to copy?
Lifecare's advantage over rival devices is built into the implant itself: the sensor is placed under a person's skin, is designed to last at least six months, and carries its own operating energy. The CGM system requires very little operating energy, and the self-sustained sensor reads glucose data continuously.
Most approved CGM devices on the market from Dexcom, Medtronic and Abbott attach to the skin with a small needle and typically last 7-15 days. The Eversense 365 offers the alternative of an implantable sensor with a life of up to 12 months whose rechargeable, removable transmitter sits on top of the skin.
Growth Drivers
What could change its growth trajectory, and what would confirm it?
For growth, the key shift is that a selling permission now exists in Europe, because the electronics marking unlocks the commercial sale: on 26 February 2026 the electronics in Lifecare's implant system became CE marked under applicable European directives, and the veterinary product containing those electronics is CE marked under applicable EU product legislation.
During the third quarter, Lifecare produced its first functional CGM implants at the Bergen facilities, and October runs and batches indicated progress toward repeatable production. The Ocean TuniCell acquisition gives a faster, more capital-efficient route to controlled manufacturing capabilities than establishing equivalent infrastructure on its own.
Market Outlook
Is its category moving in its favor or against it?
Diabetes prevalence is the category shift that favors Lifecare: the International Diabetes Federation estimates about 537 million adults lived with diabetes in 2021, a number projected to grow to about 643 million by 2030 and 783 million by 2045, and the buyers are adults living with diabetes, only a small number of whom use a continuous glucose monitor today, with use varying by region and country.
Dexcom, Medtronic, Abbott, Senseonics and Roche are among the largest healthcare companies internationally that provide a diabetes product offering. Polaris Market Research projects the continuous glucose monitoring market Lifecare would sell into will reach USD 50.21 billion by 2034, a compound annual growth rate of 15.50% during 2026–2034.
Risk Factors
Which risks could break the thesis, and what would warn of them?
Financing is the risk that could end the case, because Lifecare's cash declined to NOK 30.3 million at September 30 from NOK 36.8 million at the start of the quarter and management expects the runway under the current operating plan to extend into Q2 2027. Revenue and other income totaled NOK 420,000 in the third quarter of 2026, slightly below the NOK 537,000 recorded a year earlier, reflecting the company's pre-commercial stage.
Manufacturing and regulatory readiness is the risk that could hold up the case, because reproducibility across production runs, traceable defined procedures with quality controls, and verified and validated processes remain outstanding before Lifecare can claim controlled manufacturing. Lifecare will not fix a specific regulatory submission timeline until the required documentation and all verification and validation work are complete.
